1 / 17

Presented By Joyce Liu at 2014 ASCO Annual Meeting

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone in Recurrent Platinum-sensitive Ovarian Cancer. Presented By Joyce Liu at 2014 ASCO Annual Meeting.

stasia
Download Presentation

Presented By Joyce Liu at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone in Recurrent Platinum-sensitive Ovarian Cancer Presented By Joyce Liu at 2014 ASCO Annual Meeting

  2. Background: cediranib and olaparib are active agents in ovarian cancer Presented By Joyce Liu at 2014 ASCO Annual Meeting

  3. Cediranib and olaparib have synergistic activity in vitro Presented By Joyce Liu at 2014 ASCO Annual Meeting

  4. Phase 1 study of cediranib and olaparib demonstrated activity in ovarian cancer patients Presented By Joyce Liu at 2014 ASCO Annual Meeting

  5. Study Objectives Presented By Joyce Liu at 2014 ASCO Annual Meeting

  6. Study Design Presented By Joyce Liu at 2014 ASCO Annual Meeting

  7. Key eligibility criteria Presented By Joyce Liu at 2014 ASCO Annual Meeting

  8. Statistical Considerations Presented By Joyce Liu at 2014 ASCO Annual Meeting

  9. Study Status and Data Analysis Presented By Joyce Liu at 2014 ASCO Annual Meeting

  10. Patient Characteristics Presented By Joyce Liu at 2014 ASCO Annual Meeting

  11. Primary Outcome: Cediranib/olaparib significantly increased PFS compared to olaparib alone Presented By Joyce Liu at 2014 ASCO Annual Meeting

  12. Secondary Outcome: Cediranib/olaparib significantly increased overall response rate (ORR) compared to olaparib alone Presented By Joyce Liu at 2014 ASCO Annual Meeting

  13. Cediranib/olaparib significantly increased PFS in patients without a BRCA mutation Presented By Joyce Liu at 2014 ASCO Annual Meeting

  14. Treatment-related Adverse Events Presented By Joyce Liu at 2014 ASCO Annual Meeting

  15. Tolerability of cediranib/olaparib combination Presented By Joyce Liu at 2014 ASCO Annual Meeting

  16. Conclusions Presented By Joyce Liu at 2014 ASCO Annual Meeting

  17. Acknowledgments Presented By Joyce Liu at 2014 ASCO Annual Meeting

More Related